Total Payments
$3,806
2024 Payments
$68.49
Companies
25
Transactions
141
Medicare Patients
1,382
Medicare Billing
$322,105
Payment Breakdown by Category
Food & Beverage$2,649 (69.6%)
Research$792.31 (20.8%)
Consulting$365.00 (9.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,649 | 139 | 69.6% |
| Unspecified | $792.31 | 1 | 20.8% |
| Consulting Fee | $365.00 | 1 | 9.6% |
Payments by Type
General
$3,014
140 transactions
Research
$792.31
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| West-Ward Pharmaceuticals | $792.31 | 1 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $375.90 | 20 | $0 (2024) |
| ABBVIE INC. | $374.03 | 21 | $0 (2023) |
| C. R. Bard, Inc. & Subsidiaries | $365.00 | 1 | $0 (2021) |
| RedHill Biopharma Inc. | $364.61 | 21 | $0 (2022) |
| Alkermes, Inc. | $321.11 | 16 | $0 (2024) |
| EMD Serono, Inc. | $218.72 | 9 | $0 (2022) |
| Scilex Pharmaceuticals Inc. | $190.23 | 10 | $0 (2022) |
| IDORSIA PHARMACEUTICALS US INC | $111.80 | 6 | $0 (2024) |
| Orexo US, Inc. | $105.23 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $68.49 | 3 | Alkermes, Inc. ($24.82) |
| 2023 | $753.13 | 40 | ABBVIE INC. ($218.39) |
| 2022 | $582.99 | 30 | ABBVIE INC. ($133.69) |
| 2021 | $741.74 | 22 | C. R. Bard, Inc. & Subsidiaries ($365.00) |
| 2020 | $281.73 | 15 | RedHill Biopharma Inc. ($130.77) |
| 2019 | $225.34 | 12 | Alkermes, Inc. ($58.80) |
| 2018 | $1,038 | 13 | West-Ward Pharmaceuticals ($792.31) |
| 2017 | $115.17 | 6 | EMD Serono, Inc. ($35.47) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/13/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: CNS | ||||||
| 02/08/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Insomnia | ||||||
| 01/29/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Gastroenterology | ||||||
| 12/18/2023 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: CNS | ||||||
| 12/16/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: INSOMNIA | ||||||
| 12/14/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Gastroenterology | ||||||
| 12/01/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2023 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: CNS | ||||||
| 11/17/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2023 | IBSA Pharma Inc. | LICART (Drug), TIROSINT, TIROSINT | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: non-opioid analgesic | ||||||
| 10/31/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: Gastroenterology | ||||||
| 10/24/2023 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: CNS | ||||||
| 10/11/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Gastroenterology | ||||||
| 10/05/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: INSOMNIA | ||||||
| 09/01/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: PAIN | ||||||
| 08/30/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Gastroenterology | ||||||
| 08/29/2023 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: CNS | ||||||
| 08/16/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Gastroenterology | ||||||
| 08/16/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $2.27 | General |
| Category: Gastroenterology | ||||||
| 07/21/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Gastroenterology | ||||||
| 07/12/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Opioid PMR Study | West-Ward Pharmaceuticals | $792.31 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 173 | 630 | $67,444 | $39,026 |
| 2022 | 12 | 313 | 1,400 | $154,341 | $88,442 |
| 2021 | 15 | 418 | 1,708 | $182,898 | $109,079 |
| 2020 | 11 | 478 | 1,545 | $173,754 | $85,558 |
Total Patients
1,382
Total Services
5,283
Medicare Billing
$322,105
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99491 | Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | Office | 2023 | 38 | 251 | $25,100 | $17,623 | 70.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 155 | $26,350 | $13,126 | 49.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 58 | $6,725 | $3,867 | 57.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 33 | 57 | $3,819 | $3,064 | 80.2% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 37 | 109 | $5,450 | $1,346 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 490 | $83,330 | $49,716 | 59.7% |
| 99491 | Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | Office | 2022 | 36 | 249 | $24,900 | $16,830 | 67.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 76 | $8,740 | $5,846 | 66.9% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 21 | 21 | $7,854 | $5,078 | 64.7% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 46 | 397 | $19,860 | $4,939 | 24.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 19 | 19 | $3,515 | $2,551 | 72.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 16 | 27 | $1,809 | $1,131 | 62.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 18 | 48 | $1,584 | $580.20 | 36.6% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 14 | 14 | $700.00 | $569.52 | 81.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 17 | 18 | $900.00 | $559.35 | 62.2% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 21 | 21 | $609.00 | $398.87 | 65.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 20 | 20 | $540.00 | $243.79 | 45.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 534 | $90,780 | $57,984 | 63.9% |
| 99491 | Chronic care management services by qualified health care professional, 30 minutes or more per calendar month | Office | 2021 | 65 | 459 | $45,900 | $31,522 | 68.7% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 58 | 426 | $21,300 | $5,368 | 25.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 65 | $7,475 | $4,955 | 66.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 15 | 15 | $2,862 | $2,175 | 76.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $4,454 | $1,993 | 44.7% |
| 20553 | Injections of trigger points in 3 or more muscles | Office | 2021 | 12 | 21 | $2,142 | $1,159 | 54.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time per calendar month | Office | 2021 | 31 | 38 | $2,546 | $1,096 | 43.1% |
About Dr. Jeffrey Kamlet, MD
Dr. Jeffrey Kamlet, MD is a Pain Medicine healthcare provider based in Miami Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124034673.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Kamlet, MD has received a total of $3,806 in payments from pharmaceutical and medical device companies, with $68.49 received in 2024. These payments were reported across 141 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,649).
As a Medicare-enrolled provider, Kamlet has provided services to 1,382 Medicare beneficiaries, totaling 5,283 services with total Medicare billing of $322,105. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Other Specialties Addiction Medicine, Internal Medicine
- Location Miami Beach, FL
- Active Since 08/01/2006
- Last Updated 01/14/2019
- Taxonomy Code 208VP0000X
- Entity Type Individual
- NPI Number 1124034673
Products in Payments
- Oxymorphone hydrochloride ER tablet (Drug) $792.31
- Movantik (Drug) $343.02
- VRAYLAR (Drug) $315.29
- RELISTOR (Drug) $299.98
- VIVITROL (Drug) $161.02
- QUVIVIQ (Drug) $111.80
- SEROSTIM (Biological) $106.67
- Vivitrol (Drug) $95.89
- ZTLido (Drug) $93.10
- MOUNJARO (Drug) $89.91
- Zubsolv (Drug) $69.67
- Vivitrol 380 mg (Drug) $64.20
- XIFAXAN (Drug) $62.54
- NURTEC ODT (Drug) $53.50
- UBRELVY (Drug) $44.21
- PROLATE (Drug) $41.45
- Qutenza (Drug) $37.81
- VIBERZI (Drug) $35.84
- NALOCET (Drug) $35.32
- SUBLOCADE (Drug) $33.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.